AMX vs NTES

AMX exhibits mixed financial health with a Piotroski F-Score of 4/9 indicating borderline stability, while the absence of an Altman Z-Score prevents a full distress risk assessment. The stock appears reasonably valued with a current price of $20.76 below the growth-based intrinsic value of $37.76, though significantly above the conservative Graham Number of $3.26. Strong operating margins and ROE outperform sector averages, but weak earnings consistency, high debt/equity, and deteriorating short-term technical trend temper optimism. Analysts recommend a 'buy' with a $23.40 target, implying moderate upside.

NetEase exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9 and a fortress balance sheet (Debt/Equity 0.04). However, there is a severe divergence between its current price ($115.87) and its conservative value benchmarks, with the Graham Number at $35.64 and Intrinsic Value at $53.76. While the P/E ratio is attractive relative to the sector, the company is facing a significant earnings contraction (-29.4% YoY) and a streak of four consecutive earnings misses. The bullish analyst consensus is currently countered by a completely bearish technical trend and deteriorating growth metrics.